Prospective Randomized Clinical Trial of Fetal Atrial Flutter & Supraventricular Tachycardia Therapy (FAST RCT)

NCT02624765 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2024-05-22

No results posted yet for this study

Summary

The Fetal Atrial Flutter and Supraventricular Tachycardia (FAST) Therapy Trial is a prospective multi-center trial that examines the efficacy and safety of standard prenatal antiarrhythmic treatment. Study components of FAST include three prospective sub-studies to determine the efficacy and safety of commonly used transplacental drug regimens in suppressing fetal AF without hydrops (Randomized Clinical Trial (RCT) A), SVT without hydrops (RCT B), and SVT with hydrops (RCT C). All RCTs are open label phase III trials of standard 1st line therapy, which either is started as monotherapy (no hydrops) or as dual therapy (hydrops).

Conditions

  • Fetal Atrial Flutter Without Hydrops
  • Fetal Supraventricular Tachycardia Without Hydrops
  • Fetal Supraventricular Tachycardia With Hydrops

Interventions

DRUG

Digoxin (monotherapy)

Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day

DRUG

Sotalol (monotherapy)

Oral dose: 80 mg TID or 120 mg BID (240 mg/day)

DRUG

Flecainide (monotherapy)

Oral dose: 100 mg TID (300 mg/day)

DRUG

Digoxin (dual therapy)

Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day

DRUG

Sotalol (dual therapy)

Oral dose: 160 mg BID (320 mg/day)

DRUG

Flecainide (dual therapy)

Oral dose:100 mg TID (300 mg/day)

Sponsors & Collaborators

  • Canadian Institutes of Health Research (CIHR)

    collaborator OTHER_GOV
  • Edgar Jaeggi

    lead OTHER

Principal Investigators

  • Edgar Jaeggi, MD · The Hospital for Sick Children, Toronto

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-02-29
Primary Completion
2024-03-31
Completion
2024-03-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Canada
  • Germany
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02624765 on ClinicalTrials.gov